Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards […]
